{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"CNS Pharmaceuticals, Inc."},"Symbol":{"label":"Symbol","value":"CNSP"},"Address":{"label":"Address","value":"2100 WEST LOOP SOUTH,SUITE 900, HOUSTON, Texas, 77027, United States"},"Phone":{"label":"Phone","value":"+1 800 946-9185"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"CNS Pharmaceuticals Inc is a preclinical stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma."},"CompanyUrl":{"label":"Company Url","value":"https://www.cnspharma.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Donald H. Picker","title":"Chief Science Officer"},{"name":"John M. Climaco","title":"President, Chief Executive Officer & Director"},{"name":"Sandra Leta Silberman","title":"Chief Medical Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}